Microneedle Flu Vaccine Market, by Vaccine Type (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine), by Virus Type (Influenza Virus Type A and Influenza Virus Type B), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) — Size, Share, Outlook, and Opportunity Analysis, 2018–2026

  • To Be Published : Oct 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Vaccine is one of the most important biologic product used to prevent from infection of various diseases such as seasonal influenza, hepatitis, polio, diphtheria, Japanese encephalitis, measles, meningococcal disease, tetanus, haemophilus influenza type b, whooping cough among others. Vaccine consists of inactivated or killed form of microorganism or its protein. Vaccine generates anti-body response, which stimulates the immune system against specific diseases. Any future infections due to microorganism can be prevented by vaccinating the patients against that specific disease. Most of the vaccines are delivered through conventional needle and syringes, which has certain challenges such as needle phobia, discomfort in older and pediatric populations, requirement of special storage infrastructure, and need to visit the healthcare facility for its administration.

Microneedle flu vaccine resolves most of the challenges caused with conventional vaccines. It is of bandage-strip sized patch, which can be easily applied all over the skin. It consists of 100 solid water-soluble needles, which are capable to penetrate skin. Vaccine is encapsulated in the needles and is released as the needle tip dissolves within minutes, once the patch is applied over the skin surface. Skin produces local immune response against pathogens in the vaccine thereby, providing response similar to that of needle-based vaccine. The patch is peeled away and discarded like a used bandage strip.

Microneedle Flu Vaccine Market - Market Dynamics

Microneedle flu vaccine is still in nascent stage of development however, after its launch it would provide various advantages over conventional needle-based vaccines, which will drive growth of the market.

Microneedle vaccine can be delivered easily at any location without special storage infrastructure, therefore it can be used even at distant location. This vaccine can be self-administered by anybody thereby, eliminating the need of clinic visit and assistance of physician. This serves as an important advantage, especially in the emerging markets, where there is severe shortage of healthcare workers. According to World Health Organization, 2017 factsheet, Africa had an average of 1.30 health workers per 1000 population in 2015, which is way below the 4.5 per 1000 required for achievement of Sustainable Development Goals (SDGs). Globally, health workforce shortage is estimated to be 14.5 million, out of which Africa has the most severe health workforce (HWF) shortage, estimated to reach 6.1 million by 2030. Microneedle vaccine can address these issues if utilized on global scale. Moreover, it would avoid deaths caused from unavailability of vaccine by improving access to vaccination. For instance, according to United Nations Development Programme, measles vaccines have averted nearly 15.6 million deaths since 2000, globally.

Microneedle vaccines are safe and without any serious life threatening or adverse effects. These vaccines do not create sharp waste, thereby eliminating the problem of discarding needles. Patients suffering with needle phobia can easily use microneedle flu vaccine. According to a study published in Behavioral Neurology, 2014, around 3-4% of the world population faces needle phobia. This impacts their hospital or clinic visits, as they avoid visiting such facilities due to fear of exposure to needles. Needle phobia also impacts the vaccination amongst children, as most of them perceives injecting vaccine as a painful procedure. According to a study published in the Clinical Journal of Pain in 2015, there were 12 billion vaccination every year worldwide, most of which required injecting drug with a needle syringe system. Microneedle vaccine could reduce overall cost of vaccination.

However, there are certain limitations in the development of microneedle flu vaccine market such as problem in commercialization due to limited investment in scalable aseptic manufacturing, once product is completed with development stage.

Microneedle Flu Vaccine Market – Regional Insights.

On the basis of geography, the global microneedle flu vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America would be dominant region in the global microneedle flu vaccine market during the forecast period. This is owing to the need of large number of influenza vaccines each year and current ongoing research over microneedle flu vaccine in the region. In June 2017, National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University published a report in the journal Lancet, which shows that an influenza vaccine can produce robust immune responses and be administered safely with an experimental patch of dissolving microneedle. Participants in the study preferred microneedle flu vaccine over other types of vaccines.

There is increased amount of research funding to develop commercially available micro needle flu vaccine, which would pace up the launch of these products. In 2015, the Georgia Institute of Technology and Micron Biomedical were awarded US$ 2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. This would also widen up the disease profile for which microneedle vaccine could be developed.

Growing instances of influenza flu pandemics in the U.S. would promote faster development of microneedle vaccines with reduced vaccination cost and no special need of storage conditions. According to Centers for Disease Control and Prevention, February 2018 report, during October 2017 and February 2018, clinical laboratories tested 666,493 specimens for influenza virus, 124,316 (18.7%) of which tested positive for influenza virus and 84.3% tested positive for influenza A virus.

Key players in the global microneedle flu vaccine market are Micron Biomedical, Microdermics Inc., 3M Company, Inc., VaxInnate, and Vetter among others.

Microneedle Flu Vaccine Market Taxonomy

On the basis of vaccine type, the global microneedle flu vaccine market is segmented into:

  • Trivalent Flu Vaccine
  • Quadrivalent Flu Vaccine

On the basis of virus type, the global microneedle flu vaccine market is segmented into:

  • Influenza Virus Type- A
  • Influenza Virus Type- B

On the basis of geography, the global microneedle flu vaccine market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.